PANRETIN

LOE Approaching

alitretinoin

NDATOPICALGELPriority Review
Approved
Feb 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

(9-cis-retinoic acid) is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptor subtypes (RARα, RARβ, RARγ, RXRα, RXRβ and RXRγ). Once activated these receptors function as transcription factors that regulate the expression of genes that…

Pharmacologic Class:

Retinoid

Clinical Trials (5)

NCT04278417Phase 3Completed

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

Started Nov 2020
689 enrolled
Proliferative Diabetic Retinopathy
NCT01489189Phase 3Completed

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Started Mar 2012
305 enrolled
Proliferative Diabetic Retinopathy
NCT01407679Phase 2Terminated

Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus

Started Aug 2011
7 enrolled
Lupus Erythematosus, Cutaneous
NCT01245140Phase 2Completed

Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis

Started Apr 2011
33 enrolled
Psoriasis
NCT00841373Phase 1/2Completed

Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease

Started Jul 2007
1 enrolled
Retinal Ischemia
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers